logo
  • Home
  • About
  • Team
  • Partner Opportunities
  • Product Development
  • News
  • Contact
  • Home
  • About
  • Team
  • Partner Opportunities
  • Product Development
  • News
  • Contact

news

ConverGene Announces Sponsored Research Agreement with MD Anderson

  • 3791343
  • news
  • Sep 18, 2017
CAMBRIDGE, Md., Sept. 18, 2017 (GLOBE NEWSWIRE) — ConverGene is pleased to announce that it has entered into a collaboration with The

Continue Reading

First-In-Class Dual Beti/DRD2 at AACR

  • 3791343
  • news
  • Apr 10, 2017
ConverGene Poster On First-In-Class Dual Beti/DRD2 at AACR enthusiastically received at AACR Weds April 6, 2017. See the Poster.

Continue Reading

ConverGene Announces CRADA Agreement with The National Institute of Neurological Disorders and Stroke

  • 3791343
  • news
  • Apr 6, 2017
CAMBRIDGE, Md., April 05, 2017 (GLOBE NEWSWIRE) — ConverGene has entered into a Collaborative Research and Development Agreement (CRADA)

Continue Reading

ConverGene Announces Sponsored Research Agreement

  • 3791343
  • news, Uncategorized
  • Jan 25, 2017
with University of Maryland, Baltimore to Evaluate First-in-class Anti-cancer Agents

Continue Reading

ConverGene entered into an exclusive license agreement

  • 3791343
  • news
  • Jan 2, 2017
with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health. Under this agreement,

Continue Reading

ConverGene Advances NCATS Collaboration, Biocentury Article.

  • 3791343
  • news
  • Jan 2, 2017

Continue Reading

  © 2017 ConverGene LLC, All Rights Reserved.